back to list

Henry Wendt

SmithKline Beckman

1982 - 1989

Healthcare

1980 b. 1934
male
EducationOneDegree
UndergraduatePrinceton University
Personal
Born-Died1934
BirthplaceNew Jersey (NJ)
RaceWhite
FatherWhite Collar Worker
Era - 1980

In his term as CEO of the pharmaceutical giant, Wendt focused on a “3 point strategy” to help strengthen the business. His strategy consisted of increasing support of SmithKline’s best products, such as Tagamet, weeding out other unprofitable drugs, and increasing shareholder value. While this strategy did not provide a rapid growth spurt for SmithKline, it did lead to the successful merger of SmithKline with UK-based Beecham Company. The creation of SmithKline Beecham (SKB), engineered by Wendt and Beecham’s chief, created the world’s second largest pharmaceutical company in both prescription and over-the-counter drugs.